A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients.
Phase of Trial: Phase III
Latest Information Update: 17 Nov 2014
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 06 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 27 Dec 2010 New trial record